US wants 6 million Cue test-kits by Mar 2021
By Monitoring DeskWednesday – October 14, 2020
According to a press release, the US DoD awarded a $481 million OTA to Cue Health to increase domestic production capacity of point-of-care testing
The Cue COVID-19 is a molecular test that detects the ribonucleic acid (RNA) of SARS-CoV-2, the virus that causes COVID-19, in about 20 minutes using a nasal swab sample taken from the lower part of the nose using the Cue sample wand.
Cue’s COVID-19 test runs on the compact and portable Cue health monitoring system (CHMS) and a single-use COVID-19 test kit, includes a COVID-19 test cartridge and a Cue sample wand.
The system can be used for analysis of nasal specimens at the point-of-care and transmits test results to the Cue health app on a connected mobile smart device.
The US food and drug administration (FDA) emergency use authorisation allows the Cue COVID-19 test to be used in patient care settings under the supervision of qualified medical personnel.
This effort is being led by the US DoD’s joint programme executive office for chemical, biological, radiological and nuclear defense (JPEO-CBRND), in coordination with the US DoD defense assisted acquisition cell (DA2) and funded through the HHSD office of the assistant secretary for health to enable and support domestic production of critical medical resources.